1
Clinical Trials associated with Anti-mesothelin CAR-T cell therapy (Marino Biotechnology) / Unknown statusPhase 1IIT A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting Mesothelin in Patients With Recurred or Metastatic Malignant Tumors
This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or metastatic malignant tumors.
100 Clinical Results associated with Anti-mesothelin CAR-T cell therapy (Marino Biotechnology)
100 Translational Medicine associated with Anti-mesothelin CAR-T cell therapy (Marino Biotechnology)
100 Patents (Medical) associated with Anti-mesothelin CAR-T cell therapy (Marino Biotechnology)
100 Deals associated with Anti-mesothelin CAR-T cell therapy (Marino Biotechnology)